Anacetrapib - Merck

Drug Profile

Anacetrapib - Merck

Alternative Names: Anacetrapib; MK-0859

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; University of Oxford
  • Class Antihyperlipidaemics; Oxazolidinones; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 11 Oct 2017 Merck announces intention to not submit applications for regulatory approval of anacetrapib
  • 31 Aug 2017 Adverse events and efficacy data from the phase III REVEAL trial in Atherosclerosis released by Merck
  • 27 Jun 2017 Updated efficacy and adverse events data from the phase III REVEAL trial in atherosclerosis released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top